BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)
PLK2 [1]
(Cell-free assay)
PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 M4jCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMEC3O|Yh|ryP NFvKOVhUSU6JRWK=
ACN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEC4OFMh|ryP NHfvXlBUSU6JRWK=
TE-8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjS[nVKSzVyPUCuNFA6PDFizszN MWLTRW5ITVJ?
LC-2-ad NFzlZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjPTWM2OD1yLkCxNFk{KM7:TR?= NYfkUJN[W0GQR1XS
ALL-PO NF;VXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;abpNEUUN3ME2wMlAyOyEQvF2= M1zD[3NCVkeHUh?=
EW-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXCTWM2OD1yLkCxN|M3KM7:TR?= M33JdnNCVkeHUh?=
KM12 NWnRdYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEGzOFgh|ryP M1zCUnNCVkeHUh?=
GI-1 M17FOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j1U2lEPTB;MD6wNVM5OyEQvF2= NXHRTWlVW0GQR1XS
LS-411N NVfmU2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qVWlEPTB;MD6wNVQxPyEQvF2= MVrTRW5ITVJ?
ES8 NXfQO2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;IOGlEPTB;MD6wNVQ6PCEQvF2= NVLBOJB5W0GQR1XS
SNU-C2B MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3nVYhKSzVyPUCuNFE2OjZizszN M3rOcHNCVkeHUh?=
CESS NUPvPW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO3SlJQUUN3ME2wMlAyPjB{IN88US=> NVn3c3NLW0GQR1XS
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TkeWlEPTB;MD6wNVY3QCEQvF2= NEDtZYhUSU6JRWK=
NCI-H1963 NFrNWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7PWlg2UUN3ME2wMlAyPjd|IN88US=> M1G2W3NCVkeHUh?=
IA-LM M{O4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEG2PFgh|ryP MVzTRW5ITVJ?
SW954 NWDRfIdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPBTWM2OD1yLkCxO|A2KM7:TR?= MmnIV2FPT0WU
RL95-2 NEfwOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnpW205UUN3ME2wMlAyPzN6IN88US=> NXLQeJY6W0GQR1XS
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH2bIVEUUN3ME2wMlAyPzdizszN M4jpT3NCVkeHUh?=
OCUB-M NXXNZYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rLOmlEPTB;MD6wNVgzPiEQvF2= MUXTRW5ITVJ?
RKO NHLoOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDXTWM2OD1yLkCxPVg4KM7:TR?= NHXWdY9USU6JRWK=
LOUCY NHjKPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDrSZVkUUN3ME2wMlAzODVizszN NXv2No1jW0GQR1XS
NOS-1 NUXXdoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL2XnpKSzVyPUCuNFIxQTNizszN MlzJV2FPT0WU
A4-Fuk NInQdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL5TWM2OD1yLkCyNlE5KM7:TR?= MV3TRW5ITVJ?
A388 NV\rVFJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzITWM2OD1yLkCyNlI4KM7:TR?= NWjyToh1W0GQR1XS
TE-9 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHwTWM2OD1yLkCyNlYyKM7:TR?= NYPVW3pEW0GQR1XS
KURAMOCHI M2LMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PzNmlEPTB;MD6wNlI5PSEQvF2= M{\XV3NCVkeHUh?=
KALS-1 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GyTWlEPTB;MD6wNlM{QCEQvF2= NYXzfZFPW0GQR1XS
HOP-62 M2LkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC1TWM2OD1yLkCyOFIh|ryP NHj1TVZUSU6JRWK=
RPMI-8402 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEK1NFgh|ryP NXXjPXZVW0GQR1XS
TE-1 NIDPPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7BTWM2OD1yLkCyOVEzKM7:TR?= M3\VVHNCVkeHUh?=
CCRF-CEM NGTMeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEK1OFMh|ryP M3n0WHNCVkeHUh?=
HUTU-80 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzKTWM2OD1yLkCyOlI1KM7:TR?= M2TNRXNCVkeHUh?=
NCI-H1648 NIfXVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fjZ2lEPTB;MD6wNlY1PyEQvF2= MlvPV2FPT0WU
HCE-4 NIHscmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfNWHlpUUN3ME2wMlAzPjh{IN88US=> MUPTRW5ITVJ?
ETK-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LjWGlEPTB;MD6wNlc{PiEQvF2= M4rZN3NCVkeHUh?=
TE-15 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1TY9KSzVyPUCuNFI4OzhizszN NHfBfVFUSU6JRWK=
BE-13 NWDVRo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqyTWM2OD1yLkCyO|Qh|ryP Ml;vV2FPT0WU
KE-37 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjoTWM2OD1yLkCyO|QyKM7:TR?= MXHTRW5ITVJ?
NCI-H1355 NXTIT|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfYWVJKSzVyPUCuNFI4QDNizszN MVjTRW5ITVJ?
TE-11 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S3UWlEPTB;MD6wNlgxQSEQvF2= M17KW3NCVkeHUh?=
BL-70 M17oZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme5TWM2OD1yLkCyPFU4KM7:TR?= NITDSHlUSU6JRWK=
ES6 NFjBWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ZTWM2OD1yLkCyPFgyKM7:TR?= NHPJXnhUSU6JRWK=
GT3TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEK5OVMh|ryP NXz3PI9LW0GQR1XS
LB647-SCLC MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPQdVdKSzVyPUCuNFMyQTVizszN NYfuOlNqW0GQR1XS
NB13 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnJWYJKSzVyPUCuNFM{OTZizszN MlTRV2FPT0WU
ST486 M3G4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPHNY1KSzVyPUCuNFM{OzdizszN NETiVJNUSU6JRWK=
NCI-H82 M{PWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV36enVHUUN3ME2wMlA{OzR|IN88US=> NFzjNGdUSU6JRWK=
NTERA-S-cl-D1 NEHSTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEOzPVkh|ryP NX7UXGhoW0GQR1XS
ES4 NFPWWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrETWM2OD1yLkCzOFY{KM7:TR?= M3vsPHNCVkeHUh?=
SK-NEP-1 NITrc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mxWmlEPTB;MD6wN|Q6QSEQvF2= M3rXZXNCVkeHUh?=
Becker NVPqclEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K1SWlEPTB;MD6wN|U2PSEQvF2= M1nF[3NCVkeHUh?=
A101D M2XWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LPXmlEPTB;MD6wN|c1QCEQvF2= MV3TRW5ITVJ?
SK-UT-1 M3jXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXkTWM2OD1yLkCzO|c1KM7:TR?= NGHzWZFUSU6JRWK=
SW982 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrG[pNsUUN3ME2wMlA{PzlizszN NW\xOXhlW0GQR1XS
TE-10 NUGyWHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fvNWlEPTB;MD6wOFA1PiEQvF2= NV[xO4FvW0GQR1XS
OVCAR-4 NXfGNHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMESwOVkh|ryP NVvzRVRwW0GQR1XS
KP-N-YS NXTQUJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXPTFRKSzVyPUCuNFQxQDVizszN Mly5V2FPT0WU
BL-41 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYcJdKSzVyPUCuNFQyOjVizszN MYnTRW5ITVJ?
MZ1-PC NIfqS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMESxNlch|ryP NFHDZ3hUSU6JRWK=
PF-382 M3nnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:zTWM2OD1yLkC0NVk5KM7:TR?= MXXTRW5ITVJ?
MOLT-13 NUn1cFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPJN49KSzVyPUCuNFQzOzhizszN NYDqfnZRW0GQR1XS
HCC1599 M33MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKyXVA{UUN3ME2wMlA1OjV6IN88US=> MW\TRW5ITVJ?
IST-MEL1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMES0OFIh|ryP NILPXGFUSU6JRWK=
LU-139 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMES0OFIh|ryP MWfTRW5ITVJ?
MS-1 M2fvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmroTWM2OD1yLkC0O|AyKM7:TR?= NWHqXHFUW0GQR1XS
MFH-ino MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomxTWM2OD1yLkC1NFA{KM7:TR?= NXv4UnlVW0GQR1XS
IMR-5 NIHKVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\BeoFOUUN3ME2wMlA2ODJzIN88US=> NGj4eIlUSU6JRWK=
TE-5 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K5fGlEPTB;MD6wOVA3OyEQvF2= MUjTRW5ITVJ?
DJM-1 NVniOopXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG0e2FzUUN3ME2wMlA2OTR{IN88US=> M2K4fnNCVkeHUh?=
NB17 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrOSFFKSzVyPUCuNFUzODdizszN M2XOcHNCVkeHUh?=
KARPAS-45 NVLMNnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpOIh{UUN3ME2wMlA2OzV6IN88US=> M4jSTnNCVkeHUh?=
TGBC1TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fNdmlEPTB;MD6wOVQxPSEQvF2= M3[2Z3NCVkeHUh?=
ML-2 MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe4SWZKSzVyPUCuNFU1OTRizszN MlrOV2FPT0WU
no-10 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofLTWM2OD1yLkC1OFc1KM7:TR?= MnfYV2FPT0WU
CTV-1 NEDnPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEW1NFIh|ryP MYHTRW5ITVJ?
SJSA-1 NYXpfIFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e4TWlEPTB;MD6wOVUzKM7:TR?= MoHwV2FPT0WU
HC-1 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;3TWM2OD1yLkC1OVk4KM7:TR?= Mn7CV2FPT0WU
TE-12 NG\JPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzZZXBKSzVyPUCuNFU3OTNizszN NGD0c2ZUSU6JRWK=
KY821 NXnISIZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGSFhKSzVyPUCuNFU3OzJizszN NV\zO2pLW0GQR1XS
TALL-1 NU\rU4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TmSGlEPTB;MD6wOVcxQCEQvF2= MUPTRW5ITVJ?
DEL NF;Qb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPZTWM2OD1yLkC1O|A6KM7:TR?= NVrUUmRlW0GQR1XS
TE-6 NXzjUYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H5[WlEPTB;MD6wOVczOiEQvF2= NWm1PZZCW0GQR1XS
SK-LMS-1 NEHXdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni4TWM2OD1yLkC1PFA2KM7:TR?= MYHTRW5ITVJ?
EW-1 NHnJUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjmPIpOUUN3ME2wMlA2QDN5IN88US=> MWPTRW5ITVJ?
8-MG-BA NH21N3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ETWM2OD1yLkC1PFUyKM7:TR?= M3Tsd3NCVkeHUh?=
NALM-6 NHfhfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEW5O|Mh|ryP NF7COJRUSU6JRWK=
LB771-HNC NGq5cHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1eWRKSzVyPUCuNFU6PzlizszN NFzWRnJUSU6JRWK=
HT-144 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETMbJJKSzVyPUCuNFYyOyEQvF2= MUHTRW5ITVJ?
KM-H2 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HCNmlEPTB;MD6wOlIzOSEQvF2= NG\wO3FUSU6JRWK=
SF268 NV7vUpdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe0Z|RKSzVyPUCuNFYzQDZizszN MUjTRW5ITVJ?
RS4-11 M2C0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\EPWlEPTB;MD6wOlMxPCEQvF2= MUPTRW5ITVJ?
MHH-PREB-1 NFHlT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfzO3I3UUN3ME2wMlA3OzF7IN88US=> NXH1cJN4W0GQR1XS
ATN-1 M{HOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonrTWM2OD1yLkC2N|Q2KM7:TR?= NIfrcWtUSU6JRWK=
BB30-HNC NHLNOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmUndKSzVyPUCuNFY1OzZizszN MWXTRW5ITVJ?
CPC-N MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;JZmlEPTB;MD6wOlUzPCEQvF2= M3X2eXNCVkeHUh?=
NB1 M4HvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD1yLkC2OlE{KM7:TR?= NGj4b|BUSU6JRWK=
KS-1 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nJU2lEPTB;MD6wOlc1QCEQvF2= NXjGVnNZW0GQR1XS
RXF393 NHraSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\oe3JOUUN3ME2wMlA3PzZ2IN88US=> NF72d|hUSU6JRWK=
IST-SL2 NIrvUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjxTWM2OD1yLkC3NFA1KM7:TR?= Mnr6V2FPT0WU
GI-ME-N NXviZ29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCXGlEPTB;MD6wO|I5PiEQvF2= MXHTRW5ITVJ?
VA-ES-BJ NGG1WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEe0O|Uh|ryP NWHCOGhjW0GQR1XS
NCI-H1581 M4faNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljOTWM2OD1yLkC3OFc5KM7:TR?= MUPTRW5ITVJ?
U-266 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDsVmRTUUN3ME2wMlA4PDl5IN88US=> MWDTRW5ITVJ?
DMS-114 NY\GTHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT5NodKSzVyPUCuNFc2OjhizszN MlH1V2FPT0WU
NCI-H187 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLrVGVzUUN3ME2wMlA4PzJ4IN88US=> Ml\4V2FPT0WU
SW962 M3vjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELIdYNKSzVyPUCuNFc5OzlizszN NGnteJBUSU6JRWK=
MONO-MAC-6 NUDvPW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3odGtFUUN3ME2wMlA4QTh4IN88US=> NYTmWJFLW0GQR1XS
MOLT-16 NX;NSIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEixNlEh|ryP NXviTpc4W0GQR1XS
KNS-42 M1i4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT3enVKSzVyPUCuNFgyPjFizszN M2P2enNCVkeHUh?=
CMK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi3VYFqUUN3ME2wMlA5OjJ3IN88US=> M3fDTXNCVkeHUh?=
Ramos-2G6-4C10 NXm3N2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7lTWM2OD1yLkC4NlI2KM7:TR?= Mo\sV2FPT0WU
Daudi MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzkc2FKSzVyPUCuNFgzPTZizszN MWjTRW5ITVJ?
NCI-H510A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnTPXRbUUN3ME2wMlA5OzN4IN88US=> NGDqWVRUSU6JRWK=
LB831-BLC NIHidnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TrN2lEPTB;MD6wPFU3OSEQvF2= NWC3[I9XW0GQR1XS
HEL NFfjZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H6RWlEPTB;MD6wPFY3QCEQvF2= NFTsWHNUSU6JRWK=
LU-134-A NEfjXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPsTWM2OD1yLkC4O|A5KM7:TR?= MkC2V2FPT0WU
NCI-H1694 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEi3OFQh|ryP MlXKV2FPT0WU
KGN NVTGXlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme1TWM2OD1yLkC4O|U6KM7:TR?= MXHTRW5ITVJ?
A253 NWLoc3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEi4NlIh|ryP MXnTRW5ITVJ?
DG-75 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEi5NlIh|ryP NWfkNG9EW0GQR1XS
MOLT-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHVTWM2OD1yLkC4PVg{KM7:TR?= MnTvV2FPT0WU
NCI-SNU-5 NF7yZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjtZnBKSzVyPUCuNFkzPThizszN M1;3TnNCVkeHUh?=
ONS-76 M2W0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7tTWM2OD1yLkC5Nlc3KM7:TR?= MmTPV2FPT0WU
NCI-H446 NUPtNJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEm0OlIh|ryP NXvPbo1rW0GQR1XS
COR-L279 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fOTWlEPTB;MD6wPVU2PiEQvF2= NFX1Um9USU6JRWK=
Calu-6 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDwPZBzUUN3ME2wMlA6PTl6IN88US=> M16w[XNCVkeHUh?=
BC-3 NWD3dlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGzTWM2OD1yLkC5OlYzKM7:TR?= NXXWTJpXW0GQR1XS
NCI-H2126 NUnJTnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILjc4NKSzVyPUCuNFk4QTFizszN NHX1eWhUSU6JRWK=
NCI-H1882 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEm4NFkh|ryP NWTEcoVnW0GQR1XS
BB65-RCC M3PTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD1yLkGwNlk1KM7:TR?= M3T2eHNCVkeHUh?=
DU-4475 NGnwTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfqem9KSzVyPUCuNVA1ODdizszN M{LneHNCVkeHUh?=
NCI-H526 NVy3TmRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTaVWRkUUN3ME2wMlExPDRizszN MkTlV2FPT0WU
NEC8 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInxNnNKSzVyPUCuNVA2OjVizszN M4XDU3NCVkeHUh?=
NCI-H1304 NUjXbpV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mzT2lEPTB;MD6xNFU6PCEQvF2= NHzsWVFUSU6JRWK=
L-540 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLPemlKSzVyPUCuNVA4ODhizszN Mo\lV2FPT0WU
NCI-SNU-16 NUjIUpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMUC3OFIh|ryP M2XZfHNCVkeHUh?=
HD-MY-Z MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv1cJdKSzVyPUCuNVA5PTZizszN NEjvdW9USU6JRWK=
K-562 NX;GeYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDxTWM2OD1yLkGwPFU5KM7:TR?= Mk\sV2FPT0WU
JAR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHZTWM2OD1yLkGwPVI2KM7:TR?= MX7TRW5ITVJ?
MZ2-MEL MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXpTWM2OD1yLkGxNFUh|ryP MmfTV2FPT0WU
L-363 M4qwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPyXpRRUUN3ME2wMlEyODd7IN88US=> NWDnUFNCW0GQR1XS
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nuNWlEPTB;MD6xNVI1OyEQvF2= MoD3V2FPT0WU
NCI-H524 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUGyO|Qh|ryP MnvmV2FPT0WU
EoL-1-cell MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHE[Y45UUN3ME2wMlEyPjd{IN88US=> M1;DcXNCVkeHUh?=
K052 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HMb2lEPTB;MD6xNVcyOiEQvF2= NVnKPJNLW0GQR1XS
TK10 NYXXb|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fubWlEPTB;MD6xNVczQCEQvF2= NUPGZ|JFW0GQR1XS
KU812 NVnZbpJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDn[mVtUUN3ME2wMlEzODR2IN88US=> MVHTRW5ITVJ?
RPMI-8226 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK0TWM2OD1yLkGyNFUzKM7:TR?= MkXTV2FPT0WU
MZ7-mel MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjlPVNKSzVyPUCuNVIzOzdizszN NFfOeIpUSU6JRWK=
SK-PN-DW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[0e2lEPTB;MD6xNlI5PyEQvF2= MV3TRW5ITVJ?
SR M4TneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMUK0OFEh|ryP NHX2fXdUSU6JRWK=
RPMI-6666 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXITWM2OD1yLkGyO|Q{KM7:TR?= NUm3PWkzW0GQR1XS
no-11 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMUK4Olkh|ryP MY\TRW5ITVJ?
EW-3 NYGyUJhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLwOVJvUUN3ME2wMlEzQDl|IN88US=> NWPKemVNW0GQR1XS
LAMA-84 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMUOxPFch|ryP MlLWV2FPT0WU
HT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLiTWM2OD1yLkGzOVc1KM7:TR?= NV7LXIJzW0GQR1XS
KP-N-RT-BM-1 M2PLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLlTWM2OD1yLkGzOlEzKM7:TR?= MlLHV2FPT0WU
NCI-H747 NHuwV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\NTWM2OD1yLkGzO{DPxE1? MnrtV2FPT0WU
NCCIT MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHITWM2OD1yLkGzPVM6KM7:TR?= NITZW25USU6JRWK=
MLMA NILXO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUSxOlch|ryP M{DudXNCVkeHUh?=
LP-1 M{\ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfaRYw1UUN3ME2wMlE1OjRizszN NHPpR4lUSU6JRWK=
CAL-148 NWHWSG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;iTWM2OD1yLkG0OFg{KM7:TR?= MYDTRW5ITVJ?
GB-1 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jBWmlEPTB;MD6xOFUzPiEQvF2= M{HHSnNCVkeHUh?=
COR-L88 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHjTWM2OD1yLkG0PFAzKM7:TR?= M2i0TXNCVkeHUh?=
NKM-1 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxdINKSzVyPUCuNVQ6ODZizszN MVvTRW5ITVJ?
NB5 NEnlendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrkWllxUUN3ME2wMlE2PDZ{IN88US=> M2\vdHNCVkeHUh?=
SH-4 M2ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfjOIRRUUN3ME2wMlE2PDZ4IN88US=> NVzRU3B5W0GQR1XS
EM-2 M2nwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7tZ4FKSzVyPUCuNVU1PjdizszN MWnTRW5ITVJ?
TGBC24TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1yLkG1OlU6KM7:TR?= NX;pcVl{W0GQR1XS
SCLC-21H NXvyR3MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnWZFKSzVyPUCuNVU4ODJizszN NFfGOY5USU6JRWK=
COLO-684 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmwd|F3UUN3ME2wMlE2PzJzIN88US=> NGLhW|RUSU6JRWK=
KINGS-1 NUPZSIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMUW5NUDPxE1? M2LufXNCVkeHUh?=
LS-123 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMUW5NVch|ryP MUDTRW5ITVJ?
MC116 M3PJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMU[xOVgh|ryP Mlz4V2FPT0WU
SU-DHL-1 NXK4[YN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrINmpoUUN3ME2wMlE3OjB4IN88US=> MV7TRW5ITVJ?
NCI-H64 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTFNIVKSzVyPUCuNVY{PDdizszN MYTTRW5ITVJ?
HCE-T MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXsW3NLUUN3ME2wMlE3PTB2IN88US=> MlLmV2FPT0WU
LOXIMVI MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMU[5OFkh|ryP NUfLWZBCW0GQR1XS
ARH-77 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD1yLkG3N|c6KM7:TR?= NFvBfmhUSU6JRWK=
DOHH-2 NXLybpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQOVVKSzVyPUCuNVc3PzJizszN NETTdHNUSU6JRWK=
COLO-320-HSR M13xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzOUWdKSzVyPUCuNVgyPTRizszN M4rDeHNCVkeHUh?=
NB6 M3TB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TITWlEPTB;MD6xPFU3PiEQvF2= NW\hVWRZW0GQR1XS
L-428 NIqzRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETTUYxKSzVyPUCuNVg5OTNizszN M1HUWHNCVkeHUh?=
SNB75 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO3NWtyUUN3ME2wMlE5QDJ2IN88US=> M2XnU3NCVkeHUh?=
NCI-H2141 M3r0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTFTWM2OD1yLkG5NFEyKM7:TR?= NHn2W4dUSU6JRWK=
KARPAS-299 M3vLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz1eZFbUUN3ME2wMlE6OjRzIN88US=> NGnRcGNUSU6JRWK=
LC4-1 NYXjfnRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMUm1NFIh|ryP M3zBd3NCVkeHUh?=
UACC-257 M3nzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPkNFZnUUN3ME2wMlE6QTR5IN88US=> MXnTRW5ITVJ?
EVSA-T MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjMfHYyUUN3ME2wMlIxOzF{IN88US=> NX;Me4MxW0GQR1XS
JiyoyeP-2003 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHaSnVsUUN3ME2wMlIxPDd5IN88US=> MY\TRW5ITVJ?
NCI-H720 M3HHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrmTWM2OD1yLkKwOVI2KM7:TR?= NGTaRpFUSU6JRWK=
GAK M4T0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj0N45NUUN3ME2wMlIyOTh7IN88US=> MkXBV2FPT0WU
HH MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDuOFN5UUN3ME2wMlIyPDB3IN88US=> Ml;HV2FPT0WU
NCI-H1436 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHISIVKSzVyPUCuNlE1PjRizszN MXHTRW5ITVJ?
GR-ST NXnjeVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMkG0PFgh|ryP M3nSTHNCVkeHUh?=
BC-1 M3\wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMkK2NVYh|ryP MojwV2FPT0WU
SIG-M5 NIPvUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrUc4RyUUN3ME2wMlIzPzJ5IN88US=> M37pZ3NCVkeHUh?=
NCI-H345 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uyZWlEPTB;MD6yN|gxPSEQvF2= NHvFTpZUSU6JRWK=
OPM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5cGlEPTB;MD6yN|g5OiEQvF2= M1zNO3NCVkeHUh?=
LB1047-RCC Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMkS0NUDPxE1? NYnwSZBFW0GQR1XS
CTB-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7vTWM2OD1yLkK0OFk{KM7:TR?= NX7mUZBjW0GQR1XS
A3-KAW MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfMcpl3UUN3ME2wMlI2OzRzIN88US=> M1LVS3NCVkeHUh?=
SF126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hTWM2OD1yLkK1N|g{KM7:TR?= MYrTRW5ITVJ?
KARPAS-422 NV;nNm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLJPWlvUUN3ME2wMlI2PDN3IN88US=> M1Pj[3NCVkeHUh?=
MEG-01 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPlTWM2OD1yLkK1Olc{KM7:TR?= Ml7hV2FPT0WU
NCI-H209 NGDLb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HPdmlEPTB;MD6yOlM4PCEQvF2= NXyxTnFWW0GQR1XS
SBC-1 NXzPdIRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMk[1JO69VQ>? M3z5UHNCVkeHUh?=
K5 NWLaTJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLKbGxRUUN3ME2wMlI3QTh2IN88US=> NVfscIR4W0GQR1XS
QIMR-WIL MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nZXGlEPTB;MD6yO|E2PSEQvF2= MVnTRW5ITVJ?
NMC-G1 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTrTWM2OD1yLkK4NlE4KM7:TR?= M{LqXHNCVkeHUh?=
IST-MES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv1UolQUUN3ME2wMlI6OjN6IN88US=> MojoV2FPT0WU
SW684 NGjVR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwM{CwOFch|ryP NI\6WFBUSU6JRWK=
MV-4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XnfWlEPTB;MD6zNFc5QCEQvF2= MnXHV2FPT0WU
LAN-6 NX7URotuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwM{G1O|Ih|ryP NH;mR|NUSU6JRWK=
RH-1 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\QTWM2OD1yLkOxPFcyKM7:TR?= MlHGV2FPT0WU
CP66-MEL M1T5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr5[mFJUUN3ME2wMlMyQDd6IN88US=> MVLTRW5ITVJ?
EC-GI-10 M3;vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlOHJKSzVyPUCuN|I6QDdizszN NX3Mem16W0GQR1XS
GDM-1 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ixUmlEPTB;MD6zN|A2QSEQvF2= MnqxV2FPT0WU
IST-SL1 NWXXN3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kcWlEPTB;MD6zOFkyPCEQvF2= MYrTRW5ITVJ?
KMOE-2 NWH3S3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjPR41nUUN3ME2wMlM2OTd3IN88US=> MXnTRW5ITVJ?
OS-RC-2 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm0TWM2OD1yLkO1OVQ1KM7:TR?= MlvYV2FPT0WU
HDLM-2 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{e4NVQh|ryP MknjV2FPT0WU
DSH1 NHywS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT4TWM2OD1yLkO4OlMyKM7:TR?= MUjTRW5ITVJ?
LS-1034 M4jZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwM{i5OVQh|ryP M{\HPHNCVkeHUh?=
LB373-MEL-D NFWxcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD1yLkO5NVk4KM7:TR?= MYfTRW5ITVJ?
GOTO NGW4bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mwfmlEPTB;MD60NlEyQCEQvF2= MkHHV2FPT0WU
MRK-nu-1 M3LiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIruUoRKSzVyPUCuOFIzODVizszN M1XjR3NCVkeHUh?=
SK-MM-2 NG\3fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNEO0OFIh|ryP MlXBV2FPT0WU
BOKU NHjLVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqcWlEPTB;MD60N|c6OiEQvF2= NVLRXJlJW0GQR1XS
NOMO-1 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD1yLkSzPFYh|ryP NVfCbGRKW0GQR1XS
J-RT3-T3-5 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTHUHRKSzVyPUCuOFQ5PzhizszN MoHRV2FPT0WU
COLO-668 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\oOohyUUN3ME2wMlQ2PjZ6IN88US=> MVvTRW5ITVJ?
SF539 NIi4SW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:zVXVKSzVyPUCuOFg3QDRizszN M3S0V3NCVkeHUh?=
LB2518-MEL NXjzOldrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHMTWM2OD1yLkS5O|A{KM7:TR?= NEjJcYhUSU6JRWK=
TE-441-T MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwNUCxNkDPxE1? NYrLcVBGW0GQR1XS
MDA-MB-134-VI MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPMcHlKSzVyPUCuOVA6OjFizszN MXzTRW5ITVJ?
SCC-3 NYf2TpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrJb2JLUUN3ME2wMlUyQDd|IN88US=> NIm4cmVUSU6JRWK=
KLE Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNUKxO|Eh|ryP MlTZV2FPT0WU
LB2241-RCC M2jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqzTWM2OD1yLkWyOVI2KM7:TR?= MWrTRW5ITVJ?
NCI-H1417 M13NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1[WlEPTB;MD61N|Q{PSEQvF2= NWDnXJNpW0GQR1XS
NCI-H2081 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaT5F3UUN3ME2wMlU5PjFzIN88US=> NELX[2NUSU6JRWK=
NCI-H1522 NYfHUY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD1yLkW5N|g{KM7:TR?= NHXzVZdUSU6JRWK=
NCI-H889 NVT5[IxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXhVJRMUUN3ME2wMlU6QDR2IN88US=> M332PHNCVkeHUh?=
CGTH-W-1 M2LvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW4SJhKSzVyPUCuOlA4PTVizszN NEK4dmJUSU6JRWK=
EB-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnjbnRKSzVyPUCuOlEyPTNizszN MljIV2FPT0WU
D-336MG MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljqTWM2OD1yLk[xO|kyKM7:TR?= MXvTRW5ITVJ?
LC-1F NUjy[YVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT1eWpUUUN3ME2wMlYzPTl{IN88US=> MXfTRW5ITVJ?
MHH-NB-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3MTWM2OD1yLk[zPFAyKM7:TR?= MUDTRW5ITVJ?
SK-N-FI NYrDOGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nKUWlEPTB;MD62N|kyKM7:TR?= M4HNWXNCVkeHUh?=
NCI-H69 NHzncW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S2W2lEPTB;MD62OFg4QSEQvF2= NFLPc5ZUSU6JRWK=
SCH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNk[wNlMh|ryP M3S3OXNCVkeHUh?=
LS-513 NYn1PYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD1yLk[3NlU6KM7:TR?= NVq4Oms3W0GQR1XS
CP67-MEL M{D2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnPdmVKSzVyPUCuOlc2QTZizszN NInLfIVUSU6JRWK=
GCIY MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS0TWM2OD1yLkewN|Y{KM7:TR?= MlTSV2FPT0WU
SHP-77 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkTWM2OD1yLkewO|M1KM7:TR?= MojhV2FPT0WU
EHEB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknvTWM2OD1yLkexPFU1KM7:TR?= MUjTRW5ITVJ?
D-247MG Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHYe3hKSzVyPUCuO|MzOzJizszN MYfTRW5ITVJ?
Raji MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLMTWM2OD1yLke0PVg6KM7:TR?= NFn2bphUSU6JRWK=
MPP-89 NULYRnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXKTWM2OD1yLke1PVc5KM7:TR?= M{jIW3NCVkeHUh?=
EKVX NULadFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTlV3FKSzVyPUCuO|kxPzNizszN MkHLV2FPT0WU
HCC2218 NYe4WGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLxTnFNUUN3ME2wMlc6OTNzIN88US=> M2P0NXNCVkeHUh?=
KNS-81-FD M{S0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXWS2lKSzVyPUCuPFExOTFizszN MoXoV2FPT0WU
HCC2157 M3rBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwOES5OVEh|ryP NYnsdXN7W0GQR1XS
BT-474 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrEW|M6UUN3ME2wMlg5QDV2IN88US=> NIDHTWJUSU6JRWK=
NCI-H748 NYDidVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwOUGyJO69VQ>? MWPTRW5ITVJ?
EW-24 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G0SmlEPTB;MD65NlAxOiEQvF2= NUPxTnlvW0GQR1XS
D-263MG M{P1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TORmlEPTB;MD65OFUyOiEQvF2= NFG0WXJUSU6JRWK=
OMC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r1XmlEPTB;MD65OlM4OyEQvF2= NELBc4xUSU6JRWK=
NCI-H2196 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3XWlEPTB;MD65O|c4PyEQvF2= MUnTRW5ITVJ?
HAL-01 NG\FV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOUm4O|Ih|ryP MXTTRW5ITVJ?
NCI-H2107 NEL2RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS2TWM2OD1zLkCxPFU1KM7:TR?= MYfTRW5ITVJ?
LB996-RCC NYLjWYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrwc4tKSzVyPUGuNFgxPTFizszN MnHHV2FPT0WU
NCI-H1395 M3frWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKVZZKUUN3ME2xMlExPjdizszN MUDTRW5ITVJ?
CHP-126 M1j3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnjXFJKSzVyPUGuNVYyQTlizszN Moj3V2FPT0WU
NB69 NUWxe4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzCTWM2OD1zLkK2NVQ5KM7:TR?= MUTTRW5ITVJ?
CAS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7xZoNKSzVyPUGuN|QzOzFizszN MnvJV2FPT0WU
JVM-3 NU\Y[|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjFOo5yUUN3ME2xMlQ4QDV3IN88US=> NVvpW|NrW0GQR1XS
DMS-153 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvGdVBKSzVyPUGuOVc3PzRizszN M4j0cXNCVkeHUh?=
SK-MEL-2 NYPmeWdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD1zLkexO|g6KM7:TR?= MXTTRW5ITVJ?
NCI-H1155 M4jkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vGWWlEPTB;MT63N|Y4PiEQvF2= NV6zO5prW0GQR1XS
NCI-H1092 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHLNVFKSzVyPUGuO|YyQDJizszN M3jKVnNCVkeHUh?=
LU-165 NWTWb2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;HdGlEPTB;MT64OlQ4PiEQvF2= NVvXXFdyW0GQR1XS
HL-60 NWHpelNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3TWM2OD1zLkm5PVA5KM7:TR?= M1[0cHNCVkeHUh?=
REH M1\oUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTRllvUUN3ME2yMlAxPTh{IN88US=> M1LibnNCVkeHUh?=
JVM-2 NX3NNWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPxO2xyUUN3ME2yMlA3OTN3IN88US=> MVnTRW5ITVJ?
MN-60 M{npWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwMUezNFgh|ryP MknzV2FPT0WU
SCC-15 NFX4TVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwMkCyO{DPxE1? M4HpVHNCVkeHUh?=
SNU-C1 M4rZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i5bGlEPTB;Mj6yNVM1OyEQvF2= MXfTRW5ITVJ?
SK-MEL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzdVlOUUN3ME2yMlMzODR5IN88US=> M3n6cnNCVkeHUh?=
TGW NGfSRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwM{WwNlch|ryP MnXnV2FPT0WU
CA46 NWDHU|FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\UT4VKSzVyPUKuO|U6PjdizszN NYTaOYtrW0GQR1XS
NCI-H23 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwOEC3PVEh|ryP NHjjSnBUSU6JRWK=
MMAC-SF MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjpeJpwUUN3ME2yMlg3PjJ6IN88US=> MmX0V2FPT0WU
NCI-H2171 M1XJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnDUY5tUUN3ME2zMlA{PDR6IN88US=> MWnTRW5ITVJ?
A704 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TsdGlEPTB;Mz6xOFE6PCEQvF2= MoTxV2FPT0WU
DB NVnOb4lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPRmlEPTB;Mz6yOVU4PiEQvF2= M1\LS3NCVkeHUh?=
NCI-H719 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTyVo5KSzVyPUOuN|A{QDRizszN MkTaV2FPT0WU
MC-CAR NVX4VHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLyTWM2OD1|LkW0PFE4KM7:TR?= NFjWNIRUSU6JRWK=
SIMA NHrMRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD1|LkW4OFE3KM7:TR?= NG\PS4JUSU6JRWK=
SW872 NWfYRmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknKTWM2OD1|Lke4NVAyKM7:TR?= NHTCcXRUSU6JRWK=
HCC1187 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpZ25MUUN3ME2zMlc5OzF3IN88US=> MWfTRW5ITVJ?
EW-13 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHvTWM2OD1|LkizOFE4KM7:TR?= NH3OV2hUSU6JRWK=
NCI-SNU-1 M3TQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DXXWlEPTB;ND6yNVk6QSEQvF2= NXLENpdCW0GQR1XS
NCI-H226 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\mbllKSzVyPUSuN|M3ODZizszN Mo\GV2FPT0WU
RPMI-8866 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwM{[wNlkh|ryP Mk\3V2FPT0WU
OCI-AML2 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zGRWlEPTB;ND61OVI{KM7:TR?= NHiwVWtUSU6JRWK=
LU-65 M1Hpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwOUOwN|Mh|ryP Mkf4V2FPT0WU
SK-N-DZ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLnTWM2OD13Lk[zOFY2KM7:TR?= MkHTV2FPT0WU
NB14 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwOUexN|Uh|ryP M2DiUXNCVkeHUh?=
COLO-829 NX\5XlF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzNdJF4UUN3ME22MlM{OzV7IN88US=> M3;QRXNCVkeHUh?=
MHH-CALL-2 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfMe|JKSzVyPU[uOVE2ODhizszN MYfTRW5ITVJ?
NCI-H1770 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PoU2lEPTB;Nj62OlkxPCEQvF2= NYDFXIlbW0GQR1XS
ECC4 M37CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwOEKxO|kh|ryP MnHHV2FPT0WU
A498 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XLSGlEPTB;Nj64O|E6OiEQvF2= MlW2V2FPT0WU
DMS-79 M{Hsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fxWmlEPTB;Nz6wOFUyOiEQvF2= M1PLeXNCVkeHUh?=
P30-OHK MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7XVVV5UUN3ME23MlIyQTB4IN88US=> M1O3N3NCVkeHUh?=
D-502MG M1fxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTZnBKSzVyPUeuPVg{PiEQvF2= NXPIe3lXW0GQR1XS
RCC10RGB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfXellKSzVyPUiuNFYzQCEQvF2= M1y3fnNCVkeHUh?=
U-698-M NISzTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;xTWM2OD16LkK5NlI3KM7:TR?= NFfOTWlUSU6JRWK=
BB49-HNC NHfQUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMSmlEPTB;OT60NlI3PSEQvF2= MnLoV2FPT0WU
ES1 NH7lTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWzTWM2OD17Lk[4PVU3KM7:TR?= MYDTRW5ITVJ?
MFM-223 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFyLkm5Nlch|ryP MmnDV2FPT0WU
C2BBe1 M1S0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HlPWlEPTB;MUGuN|UzOyEQvF2= MX3TRW5ITVJ?
EB2 M1;NcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r4NmlEPTB;MUKuOlg5OSEQvF2= NYfUO5A1W0GQR1XS
C8166 NVrtS29iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrqblBXUUN3ME2xN{45OzB|IN88US=> MkDjV2FPT0WU
ES3 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQSY9KSzVyPUGzMlk6PzdizszN MV;TRW5ITVJ?
NCI-H1650 M2f5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPvclFKSzVyPUG2MlM4PjVizszN MUTTRW5ITVJ?
Mo-T NH7hTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezNG5KSzVyPUG3MlQxOjlizszN NVnqSYlEW0GQR1XS
NB7 NVW1NIVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXtbIt6UUN3ME2xO{44PDZ5IN88US=> NGjPdY1USU6JRWK=
ES7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF7LkW1NFch|ryP MVzTRW5ITVJ?
ES5 NYjLbYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJzLke2O|Eh|ryP MXrTRW5ITVJ?
MSTO-211H NVvh[YM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJzLki4OVgh|ryP MofBV2FPT0WU
U-87-MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ3LkG5OlYh|ryP Mn7FV2FPT0WU
THP-1 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ7LkeyNFEh|ryP NGS2OXZUSU6JRWK=
NB10 NX;RWIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruTWM2OD1|MD6yOlk1KM7:TR?= MluyV2FPT0WU
NH-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrUbVJlUUN3ME2zN{4zODF5IN88US=> Ml3DV2FPT0WU
COLO-824 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T4[GlEPTB;M{SuNVAxPiEQvF2= NFrjcW1USU6JRWK=
SKM-1 M1K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXETWM2OD1|Nz64OFIzKM7:TR?= MWDTRW5ITVJ?
NCI-H1838 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[2UFI3UUN3ME2zPE4{Pzl5IN88US=> M{nhWXNCVkeHUh?=
RL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN7LkK0O|ch|ryP Mle2V2FPT0WU
COLO-800 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXFTWM2OD12MD6wO|c{KM7:TR?= M1LrTHNCVkeHUh?=
KG-1 M3TGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTtTWM2OD12MD64PVU2KM7:TR?= MVfTRW5ITVJ?
TUR NELEcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD12MT62N|k6KM7:TR?= NFP3d3hUSU6JRWK=
LNCaP-Clone-FGC NWLoUpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;6cHBKSzVyPUSxMlkxOTdizszN NH3pUZFUSU6JRWK=
NCI-H322M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkNIVKSzVyPUSyMlU6QDRizszN MnTIV2FPT0WU
LNCaP  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;EXHkyUUN3ME25NU4{KG6P Mo[wNlU2ODVzN{S=
C4-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rzbGlEPTB;ODDuUS=> MkH5NlU2ODVzN{S=
JURKAT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jWbVI1KGh? MX;JR|UxRTRzNj62OkBvVQ>? MofkNlQ2OTl7OUW=
MOLT-4 M3\5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TtR|I1KGh? NGTZT|dKSzVyPUK4OVMvPSCwTR?= MmrVNlQ2OTl7OUW=
REH MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vWW96OjRiaB?= M{nudmlEPTB;Mki3MlY5KG6P M4rnSVI1PTF7OUm1
NALM-6 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnNlQhcA>? NIfLU5dKSzVyPUO0N|MxKG6P Ml7qNlQ2OTl7OUW=
RS 4;11 M4jrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT0dFczPCCq NGPaNnBKSzVyPUWxPU4xPSCwTR?= M3;xb|I1PTF7OUm1
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnUNlQhcA>? M13ad2lEPTB;MkGwO{4yKG6P NHHKNHQzPDVzOUm5OS=>
SIL-ALL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXmNlQhcA>? MWPJR|UxRTF7OT63O{BvVQ>? NHTqT2wzPDVzOUm5OS=>
CEM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW1NlQhcA>? MorUTWM2OD13Mj6xPEBvVQ>? NUjHR|VjOjR3MUm5PVU>
P12 NVmwfHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfIdIFoOjRiaB?= NUfocllMUUN3ME2zPU4zPyCwTR?= NFe1RnAzPDVzOUm5OS=>
NALM-16 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKw[WczPCCq NUPKU25XUUN3ME25Ok4zQCCwTR?= MoTINlQ2OTl7OUW=
JURKAT NUXndoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:0PEBp NH;CTYxKSzVyPUG0Mlg1KG6P MWeyOFUyQTl7NR?=
MOLT-4 M3;jV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHkW5ozPDhiaB?= MXTJR|UxRTJ4Lk[gcm0> MX[yOFUyQTl7NR?=
REH NHTFRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zVUlQ5KGh? M1v5WmlEPTB;NESuO|Ehdk1? NXjoVnBTOjR3MUm5PVU>
NALM-6 NXjkVVVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrNIU1QCCq MmL3TWM2OD1{Mz6yOkBvVQ>? MYmyOFUyQTl7NR?=
RS 4;11 NX3IfYZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG0PEBp MUDJR|UxRTF4ND6yPEBvVQ>? MYSyOFUyQTl7NR?=
697 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDqOIo1QCCq MlrZTWM2OD1|MEWuN{BvVQ>? NIe5UFgzPDVzOUm5OS=>
SIL-ALL NF\uRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi0PEBp NGfIRZhKSzVyPUe0MlYzKG6P MkPKNlQ2OTl7OUW=
CEM M1:2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[0PEBp NVG5dph2UUN3ME2yOE42PSCwTR?= NXXy[WVzOjR3MUm5PVU>
P12 NIHL[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT2[ZA1QCCq NXrKfIc2UUN3ME2xPE41PiCwTR?= MmHlNlQ2OTl7OUW=
NALM-16 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILJUnU1QCCq NXf2W4RzUUN3ME22N{4zPCCwTR?= MVyyOFUyQTl7NR?=
JURKAT NFPvUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJRohSPzJiaB?= NInPdo1KSzVyPUOuOlUhdk1? MVGyOFUyQTl7NR?=
MOLT-4 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHjeI9UPzJiaB?= NHLtcphKSzVyPUeuN|khdk1? NH7ZRWIzPDVzOUm5OS=>
REH M33oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0SWZXPzJiaB?= M{P3dGlEPTB;MU[uNFEhdk1? M3jmNFI1PTF7OUm1
NALM-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlroO|IhcA>? M3Wz[GlEPTB;MT63PEBvVQ>? NYnFfJh{OjR3MUm5PVU>
RS 4;11 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTPO|IhcA>? M1HRXmlEPTB;ND6zPEBvVQ>? NYHjXYJPOjR3MUm5PVU>
697 NITpO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPtW4w4OiCq MnjCTWM2OD15ND6yPEBvVQ>? MWOyOFUyQTl7NR?=
SIL-ALL NYm2[VhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG3NkBp NH;rTodKSzVyPUeuNkBvVQ>? MmfoNlQ2OTl7OUW=
CEM NYTyfoZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISy[4Y4OiCq NV6zNHhnUUN3ME21MlQzKG6P NE[4bmczPDVzOUm5OS=>
P12 M1;0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDLO|IhcA>? NFjwZ3pKSzVyPU[uN|chdk1? MlLVNlQ2OTl7OUW=
NALM-16 NYDofohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXNO|IhcA>? NUTFUnlTUUN3ME23O{44OyCwTR?= NHHmfG8zPDVzOUm5OS=>
Y79 M2HVfmFxd3C2b4Ppd{BCe3OjeR?= MV:xMVUxKG6P NXTuW4lROTJxMkSgbC=> M4HleWROW09? NX;ibIxJcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV NVTnNmw5OjR|Nk[2OlU>
WER-Rb-1 NIT0bYhCeG:ydH;zbZMhSXO|YYm= M{DUZVEuPTBibl2= MXGxNk8zPCCq MWrEUXNQ MXvpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS= NIHHT2MzPDN4Nk[2OS=>
G7 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNwMzDuUS=> MoLkNlQzODR5M{O=
G166 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnQNIxQUUN3ME23MlAhdk1? MVWyOFIxPDd|Mx?=
CB660 NUizOI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HqcWlEPTB;Nj60JI5O NYfmeo9JOjR{MES3N|M>
CB1117 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHyTWM2OD1zNT62JI5O MXGyOFIxPDd|Mx?=
KB-3-1 NVXITo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPrWYJSUUN3ME2xMlQ5KMLzIECuOVMhdk1? Ml3KNlM6PjJ2NEW=
KB-8-5-11 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPSTWM2OD13LkCxJOKyKDJwMEGgcm0> NX;kd3lQOjN7NkK0OFU>
KB-C-1 NWLBd3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofuTWM2OD1zNj63OkDDuSB2LkWxJI5O NWm5bHc{OjN7NkK0OFU>
KB-V-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;H[2lEPTB;MkixMlI1KMLzIEOxMlU4KG6P NXPHc5h1OjN7NkK0OFU>
OVCAR-8 NVHMeFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\QSIV{UUN3ME23MlE6KMLzIEOuOlAhdk1? MY[yN|k3OjR2NR?=
NCI-ADR-RES MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF{N{OuN|AhyrFiMUmxMlIxKG6P MXWyN|k3OjR2NR?=
MCF7 NF75cYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTVwMUGgxtEhOS52NzDuUS=> NFXZc4gzOzl4MkS0OS=>
MCF7-FLV1000 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHF[5hmUUN3ME2zPVMvOThiwsGgO|QvQDNibl2= M4jae|I{QTZ{NES1
S1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ2LkOwJOKyKDRwN{Wgcm0> MVqyN|k3OjR2NR?=
S1-M1-80 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr0XFRqUUN3ME2yOlEvODZiwsGgOFgvOjVibl2= NH7RV2QzOzl4MkS0OS=>
CORL-23/P NEfmZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe2N2tCUUN3ME20MlM5KMLzIEGuNlUhdk1? Mn3rNlM6PjJ2NEW=
CORL-23/R NYj2bVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj5cGJKSzVyPUWuNVYhyrFiMT64N{BvVQ>? MoniNlM6PjJ2NEW=
NIH3T3 NIj4fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRyLk[wJOKyKDRwOUegcm0> MnvmNlM6PjJ2NEW=
NIH3T3-G185 NGfic3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHG[3dKSzVyPUK0NVMvPDBiwsGgOFI{NjZ4IH7N NH\sdHUzOzl4MkS0OS=>
pcDNA-HEK293 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzwTnN3UUN3ME2yMlc2KMLzIECuOlchdk1? NFizcZAzOzl4MkS0OS=>
MDR19-HEK293 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz0WXZKSzVyPUi1MlUxKMLzIEGzMlY4KG6P NVfMOIFMOjN7NkK0OFU>
R482-HEK293 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ3Lkm3JOKyKDRwOUWgcm0> M3raZ|I{QTZ{NES1
MRP1-HEK293 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljUTWM2OD1{Lkm5JOKyKDFwNEmgcm0> M3e0WlI{QTZ{NES1
SF188 NUDBc5BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX4TXAyOC1zMECgcm0> M4\B[VI1NTl4IHi= MljQSG1UVw>? M{PINolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36tJIRmeGWmZX70JI1idm6nch?= MYGyN|g5PzZ2NR?=
T98G M2LNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPvNVAuOTByIH7N MV2yOE06PiCq M3TUcmROW09? MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK= MVKyN|g5PzZ2NR?=
DU145 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnBdWVUTE2VTx?= NUfI[2xUUUN3MPMIwFYxKG6P NFjjcHMzOzh6NESyPC=>
LNCaP  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETqdYxFVVOR MXjJR|Ux6oj:N{Wgcm0> MU[yN|g5PDR{OB?=
PC3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDwW|BFVVOR MX;JR|Ux6oj:MUe1JI5O M1KyTVI{QDh2NEK4
RT4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLHN5FKSzVyPUK3MlIyKG6P NUmxNnE{OjN5OUK2N|k>
5637 NGT6cXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;E[mx3UUN3ME20OU41PyCwTR?= NX64bVFCOjN5OUK2N|k>
T24 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTd7LkGyJI5O NYOzTHFwOjN5OUK2N|k>
MCF7  Mk\KSpVv[3Srb36gRZN{[Xl? Mof4NVAxKG6P MmniNUBp NGD2SXRFVVOR NHHvRlhz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3dCpGdz\WJzLNMgV4dsOS{EoGDzNkzDqFOncoDpcoE{NCCjbnVCpHdqe3B{ NGLB[oQzOzd5MEK0OC=>
KB-V1  MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfs[2g2UUN3ME2zMlkzKM7:TR?= MV6yN|U6OzF7Nh?=
Hec50co MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTVibl2= NVWyVpd{OjNzNE[2PFc>
MDA-MB-468 MYjBdI9xfG:|aYOgRZN{[Xl? M4C2ZVEwPS9zMDDuUS=> NXjNN3QxOjRxNEivO|IhcA>? MWXEUXNQ NXTQfFM{cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnHMNlMyPDR{OUS=
MCF10A MUHBdI9xfG:|aYOgRZN{[Xl? MYWxM|UwOTBibl2= MVqyOE81QC95MjDo M{DLfGROW09? M33tW4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWnqeYFvOjNzNESyPVQ>
Huh-7 NIPDXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT6SZQyNzFyL{GwNE8yODByIH7N Mn[2OFghcA>? Mmru[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5 M1nzRlIzPzR3NUi3
Daoy  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFe2MyNjh5NT2yOFAhdk1? NEfoNng4OiCq NV\EdlFpTE2VTx?= NFTkeldKSzVyPUWgcm0> M4DJdlIzOzlyMke5
ONS-76 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr0NU45PzVvMkSwJI5O NFT0UGY4OiCq MnzoSG1UVw>? NGWzTlhKSzVyPUeuOUBvVQ>? MlTpNlI{QTB{N{m=
SUM 149 NYXwe4puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;B[lAuOTByIH7N NImyfJU4OiCq NWmzZ5RZcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz NXnXe|lKOjJ|MEm5N|k>
MDA-MB-231 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fRe|AuOTByIH7N NEXiUnQ4OiCq NX7pfoF1cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz NXPoUlhZOjJ|MEm5N|k>
HR5 NGDDUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrGNE0yODBibl2= MU[3NkBp NX3xOWNDcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz M2n2ZVIzOzB7OUO5
BT-474-M1 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLuWogxNTFyMDDuUS=> MXy3NkBp MWfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= NUPRXJZnOjJ|MEm5N|k>
AU565 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPUN4IxNTFyMDDuUS=> NGrSTIo4OiCq MlvybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NVTyd2dSOjJ|MEm5N|k>
T47D NITFVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFRlAuOTByIH7N MVG3NkBp NXvmcHVVcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz M4\tdlIzOzB7OUO5
MCF7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWc4NROC1zMECgcm0> MonJO|IhcA>? M3z1c4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> NHu0cG8zOjNyOUmzPS=>
HCT116p53(+/+) NILu[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\VNVAuOTByMDDuUS=> NV7S[IxbOjRxNEigbC=> MlrmbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0> NUTu[nNvOjJ{NkKxO|E>
HCT116p53(-/-) M{jhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2THSlExNTFyMECgcm0> MlLwNlQwPDhiaB?= NHHzdnNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>? MmTUNlIzPjJzN{G=
HeLa  NYfwfJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQc|ExNTFyMDDuUS=> NVvZfY4yPDhiaB?= NVPje4R5TE2VTx?= MnHsTWM2OD13Mj65JI5O NHvKPYQzOjB6MEKzOS=>
HeLa  MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnnZ4wyOC1zMECgcm0> NXLtT3B2PzJiaB?= MUTEUXNQ NEXEN|BKSzVyPUWwMlUhdk1? MYiyNlA5ODJ|NR?=
GBC NWLZfHJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVq3NkBp M1OyVWlEPTB;MUSuO|ghdk1? M3nTe|IyQTZ3N{O5
GB-CL-1 M1LNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTTO|IhcA>? Ml60TWM2OD13LkKyJI5O NHXQR3UzOTl4NUezPS=>
Mz-ChA-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHW4M4OiCq NXnnPI1oUUN3ME2zMlMyKG6P NVXoT5NSOjF7NkW3N|k>
TGBC1-TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzNVQ1KGh? MoTqTWM2OD14LkeyJI5O NFXHeGEzOTl4NUezPS=>
Wittier MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnTfmM4OiCq MV\JR|UxRTNwMk[gcm0> NXvnWlV6OjF7NkW3N|k>
H-1 M3XTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFcVJCPzJiaB?= MYHJR|UxRTlwNUSgcm0> MUCyNVk3PTd|OR?=
HuH-28 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzaZYxHPzJiaB?= NYftXYlFUUN3ME2xNU4yQSCwTR?= NFmyTXYzOTl4NUezPS=>
NEC NXHUbIF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXGVWZIPzJiaB?= M1rVVWlEPTB;OT65PEBvVQ>? M1G5NlIyQTZ3N{O5
REB NX\zSFN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV63NkBp NHe5VnFKSzVyPUGzMlUyKG6P NF;QcY4zOTl4NUezPS=>
CC-LP-1 M3zoe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:3NkBp MX3JR|UxRTVwOESgcm0> MnzlNlE6PjV5M{m=
CC-SW-1 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq3XokxPzJiaB?= MWPJR|UxRTlwNUWgcm0> NIfzO5kzOTl4NUezPS=>
EGI-1 NGC4bJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XBVlczKGh? NX;pO5FrUUN3ME2xNE44OiCwTR?= MYqyNVk3PTd|OR?=
Sk-ChA-1 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXUVczKGh? MWTJR|UxRTF5LkKgcm0> NEj5cFczOTl4NUezPS=>
TFK-1 M1G3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1frVFczKGh? MWPJR|UxRTF|LkS1JI5O NXLVNXBZOjF7NkW3N|k>
786-O NVTzdZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPCOU05OCCwTR?= NUPEOoNHQTZiaB?= NEnQbFBJS2x? M1PlWpN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?= Mn;MNlE3PDJ|N{S=
A498 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjzW4c2NThyIH7N M{P6XVk3KGh? MnvGTGNt Mn7kd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P Mm\3NlE3PDJ|N{S=
ACHN M3vxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX21MVgxKG6P Mn3ZPVYhcA>? MWrIR4w> NEXiW49{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= MoTXNlE3PDJ|N{S=
Caki-1 NFrnXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\UdlUuQDBibl2= MmnCPVYhcA>? M2LYV2hEdA>? NV3jSopGe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N M1\2XVIyPjR{M{e0
SN12C NHfGUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX61MVgxKG6P M3:yZlk3KGh? NEWxUmdJS2x? NI\jc3N{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= MWeyNVY1OjN5NB?=
HMC-1.1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LaeFEuOTByMDDuUS=> MYe3NkBp NEfpZ41qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV? M1;JW|IyOjR{MUi5
HMC-1.2 NIfQXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHw[|I4OS1zMECwJI5O MkjRO|IhcA>? M4W2PYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? MlL1NlEzPDJzOEm=
C2 NELYbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxMVExODBibl2= NH\0eG84OiCq NWfJb454cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n NV;sV2JWOjF{NEKxPFk>
CHP-212 NWT4bGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfLWJhVOS1zMkWgcm0> NUOwWYc2OjRvMUKwJIg> MkL6bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= NGPYe2szOTF4OUK0Ni=>
IMR-32 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H1eFEuOTJ3IH7N MoTtNlQuOTJyIHi= M36xUIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MofQNlEyPjl{NEK=
Kelly NWrGXWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHB[WoyNTF{NTDuUS=> MX6yOE0yOjBiaB?= NWr6XFN2cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> M3qxWlIyOTZ7MkSy
SH-EP NWPiR5czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\MZVkyNTF{NTDuUS=> Ml;XNlQuOTJyIHi= M4rvXolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= M2exZ|IyOTZ7MkSy
SH-SY5Y NW\aXJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PJNVEuOTJ3IH7N NIG4emYzPC1zMkCgbC=> M13yc4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= M4XzfFIyOTZ7MkSy
SK-N-AS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSwO5EyNTF{NTDuUS=> NU\W[XhLOjRvMUKwJIg> M3\qPYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= M2Lvd|IyOTZ7MkSy
SK-N-BE M{fuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3vSYpUOS1zMkWgcm0> NFq5bWszPC1zMkCgbC=> NID0VXRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l NIXjdVEzOTF4OUK0Ni=>
KG1 M4XyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SwblEwOTBxMUCwJI5O M4jKOFczKGh? M{DZNmROW09? NFywUZJqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l MoPXNVk1PTh|NUi=
U937 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJNU8yOC9zMECgcm0> MmDqO|IhcA>? M2TkSGROW09? MVjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n NFvjcYsyQTR3OEO1PC=>
CAL62 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQNE4yNTFyMDDuUS=> MkfFO|IhcA>? NXnvU3RNTE2VTx?= MmL4SWM2OD1zLkSgcm0> MlfvNVkzOjN3NUO=
OCUT-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPtVVcxNjFvMUCwJI5O M4rFTVczKGh? MWfEUXNQ NXX0cmpPTUN3ME2yMlMhdk1? NIn3SJAyQTJ{M{W1Ny=>
8505C NXn6bnAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzyVJAxNjFvMUCwJI5O NIjlb5M4OiCq MlK4SG1UVw>? MWnFR|UxRTNwMjDuUS=> M37kPVE6OjJ|NUWz
ACT-1 NXPaTJVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLQUnMxNjFvMUCwJI5O Mo\HO|IhcA>? M{LkfmROW09? MV\FR|UxRTVwNDDuUS=> MnHRNVkzOjN3NUO=
SW1736 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHyUVUxNjFvMUCwJI5O NIG2VmU4OiCq NWjkSmpMTE2VTx?= MXjFR|UxRTVwNjDuUS=> M2iyfFE6OjJ|NUWz

... Click to View More Cell Line Experimental Data

In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3

CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma, Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma, Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia, Myeloid, Acute Boehringer Ingelheim October 2006 Phase 2
NCT00706498 Completed Prostatic Neoplasms Boehringer Ingelheim September 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID